Benchmark raises its price target on Buy-rated CryoLife CRY on robust outlook ahead.
Benchmark says, "Guidance for 2012 EPS was $0.14-$0.18 versus the $0.33
consensus and our $0.28 forecast. Excluding $0.12-$0.14 per share in fully-taxed
Medafor litigation expense, we equate guidance to $0.26-$0.32 in earnings power.
We increase our price target to $7.50, from $6.50, as our valuation basis shifts to
2013."
CRY closed at $5.98 a share on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in